Early sepsis diagnosis via protein and miRNA biomarkers using a novel point-of-care photonic biosensor
Fabri Faja, Nuria (Institut Català de Nanociència i Nanotecnologia)
Calvo Lozano, Olalla (Institut Català de Nanociència i Nanotecnologia)
Dey, Priyanka (Institut Català de Nanociència i Nanotecnologia)
Terborg, Roland A. (Institut de Ciències Fotòniques)
Estévez, M. Carmen (Institut Català de Nanociència i Nanotecnologia)
Belushkin, Alexander (École Polytechnique Fédérale de Lausanne)
Yesilköy, Filiz (École Polytechnique Fédérale de Lausanne)
Duempelmann, Luc (Institut de Ciències Fotòniques)
Altug, Hatice (École Polytechnique Fédérale de Lausanne)
Pruneri, Valerio (Institució Catalana de Recerca i Estudis Avançats)
Lechuga, Laura M (Institut Català de Nanociència i Nanotecnologia)

Data:	2019
Resum:	Sepsis is a condition characterized by a severe stage of blood-infection often leading to tissue damage, organ failure and finally death. Fast diagnosis and identification of the sepsis stage (sepsis, severe sepsis or septic shock) is critical for the patient's evolution and could help in defining the most adequate treatment in order to reduce its mortality. The combined detection of several biomarkers in a timely, specific and simultaneous way could ensure a more accurate diagnosis. We have designed a new optical point-of-care (POC) device based on a phase-sensitive interferometric biosensor with a label-free microarray configuration for potential high-throughput evaluation of specific sepsis biomarkers. The sensor chip, which relies on the use of metallic nanostructures, provides versatility in terms of biofunctionalization, allowing the efficient immobilization of different kind of receptors such as antibodies or oligonucleotides. We have focused on two structurally different types of biomarkers: proteins, including C-reactive protein (CRP) and Interleukin 6 (IL6), and miRNAs, using miRNA-16 as an example. Limits of Detection (LoD) of 18 μg mL, 88 μg mL and 1 μM (6 μg mL) have been respectively obtained for CRP, IL6 and miRNA-16 in individual assays, with high accuracy and reproducibility. The multiplexing capabilities have also been assessed with the simultaneous analysis of both protein biomarkers.
Ajuts:	European Commission 644956 Ministerio de Economía y Competitividad SEV-2017-0706 Ministerio de Economía y Competitividad FICTS-1420-27 Ministerio de Economía y Competitividad SEV-2015-0522 Ministerio de Economía y Competitividad TEC2016-75080-R Agència de Gestió d'Ajuts Universitaris i de Recerca 2017/SGR-1634
Drets:	Tots els drets reservats.
Llengua:	Anglès
Document:	Article ; recerca ; Versió sotmesa a revisió
Matèria:	Point-of-care ; Label-free multiplexed biosensing ; Nanoplasmonics ; Sepsis ; Protein and miRNA biomarkers ; Microarray
Publicat a:	Analytica chimica acta, Vol. 1077 (October 2019) , p. 232-242, ISSN 1873-4324

DOI: 10.1016/j.aca.2019.05.038
PMID: 31307714

Preprint 27 p, 1.1 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències > Institut Català de Nanociència i Nanotecnologia (ICN2)
Articles > Articles de recerca
Articles > Articles publicats